Install Free Gold Price Widget!
Install Free Gold Price Widget!
Install Free Gold Price Widget!
|
- Recently Published - The New England Journal of Medicine
Explore this issue of The New England Journal of Medicine (Vol 0 No 0)
- First-Line Camizestrant for Emerging - The New England Journal of Medicine
Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4 6) inhibitor for advanced breast cancer
- Zongertinib in Previously Treated - The New England Journal of Medicine
In cohort 1, a total of 75 patients received zongertinib at a dose of 120 mg At the data cutoff (November 29, 2024), 71% of these patients (95% confidence interval [CI], 60 to 80; P<0 001 against
- Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Preclinical and observational studies suggest that exercise may improve cancer outcomes However, definitive level 1 evidence is lacking In this phase 3, randomized trial conducted at 55 centers,
- Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal . . .
Tezepelumab is a human monoclonal antibody that specifically blocks TSLP from interacting with its heterodimeric receptor 21,22 Tezepelumab administered subcutaneously at a dose of 210 mg every 4
- New England Journal of Medicine
The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
- Lorundrostat Efficacy and Safety in Patients with Uncontrolled . . .
Uncontrolled hypertension remains a leading cause of cardiovascular complications and death from cardiovascular disease 1 Despite the use of multidrug regimens, reaching recommended blood
|
|
|